חוב לטווח קצר להון עצמי inovio.com (INO)

The quotes provided below demonstrate the debt-to-equity ratio of Inovio Pharmaceuticals (INO), which stands at 0.54. Inovio Pharmaceuticals (INO) is building a global immunotherapy distribution network, minimizing component supply chain disruptions. The holding company is currently preparing to launch its first commercial HPV drug in the US by 2026. However, the lack of stable revenue and slow regulatory approvals pose a serious threat to the business's financial stability.

Investors use this ratio to assess the liquidity and financial stability of the issuer. Inovio Pharmaceuticals (INO) ownership of unique DNA vaccine technology requires significant R&D operating expenses. By analyzing the history of short-term loans relative to equity, one can determine the share of short-term credit (up to one year) within the equity structure. Low values confirm the autonomy of the biopharmaceutical business and minimize the risk of default on current liabilities.